Skip to main content

Advertisement

Table 1 Subjects' clinical characteristics at baseline.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

  Placebo (25) Raloxifene (50) Tamoxifen (50)
Age (Lower-upper quartile) 44 (42-47) 46 (42-49) 45 (41-49)
Age at menarche (Lower-upper quartile) 13 (12-13) 12 (12-13) 12 (11-14)
Parity 1 2 2
Family history1 BC°- OC°° 5 - 1 15 - 1 11 - 3
Body mass index (Lower-upper quartile) 22.9 (21.7-26.2) 22.2 (20.5-24.6) 22.2 (20.3-25.2)
Smoking Never/former/current/ missing 14/3/8/0 28/10/11/1 24/5/21/0
Tumor size mm (Lower-upper quartile) 22.0 (15-30) 22.5 (15.0-28.5) 21.5 (15.0-27.5)
Tumor grade 1/2/3/unknown2 7/7/5/6 3/23/7/17 3/22/8/17
HER2 overexpression % No/yes 96/4 98/2 94/6
Luminal subtype % A/B HER2 neg/B HER2 pos 36/60/4 20/78/2 27/67/3
  1. 1First or second degree relatives with °breast cancer (BC) or °°ovarian cancer (OC); 2not graded by the pathologist.